Phenelzine sulfate

Name: Phenelzine sulfate
Brand: MedChemExpress
SKU: HY-B1018A
Rating: 5.0 (5 reviews)

Cat. No.: HY-B1018A Purity: 99.92%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (K_i: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer.

For research use only. We do not sell to patients.

Phenelzine sulfate Chemical Structure

CAS No. : 156-51-4

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Phenelzine sulfate:

Phenelzine-d₅ sulfate In-stock
Phenelzine Get quote

5 Publications Citing Use of MCE Phenelzine sulfate

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Monoamine Oxidase Isoform Specific Products:

View All Isoforms

MAO-A MAO-B

View All Histone Demethylase Isoform Specific Products:

View All Isoforms

KDM1/LSD1 KDM2 KDM3 KDM4 KDM5 KDM6 KDM7

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Phenelzine sulfate inhibits recombinant mouse MAOA/MAOB, PIPOX, PCYOX1, ALDH2 and SCRN3 proteins^[2].
Phenelzine (80 μM; 48 h; H460) sulfate reduces H460 cell proliferation by less than 50% in a [³H]thymidine incorporation assay^[3].
Phenelzine (10-100 μM; 24 h; rat retinal ganglion cells) sulfate reduces 3-Aminopropanal-induced toxicity^[1].
Phenelzine (150-300 nmol; 30 min; phosphate-buffered saline) sulfate reduces acrolein levels in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	Rat retinal ganglion cells
Concentration:	10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 100 μM
Incubation Time:	24 h
Result:	LDH release was measured 24 hours after cotreatment with 3-Aminopropanal, showing reduced toxicity.

Western Blot Analysis^[3]

Cell Line:	LNCaP
Concentration:	3 μM, 10 μM, 20 μM, 40 μM
Incubation Time:	48 h
Result:	No significant changes in H3K4Me2 or total H3 levels were observed.

Cell Proliferation Assay^[3]

Cell Line:	H460
Concentration:	80 μM
Incubation Time:	48 h
Result:	Less than 50% reduction in 3H-thymidine incorporation.

In Vivo

Phenelzine (31.6 mg/kg; drinking water; once daily; 12 weeks) sulfate exhibits lower body fat content, subcutaneous white adipose tissue (WAT) mass and lipid content in skeletal muscles than control, without decreases body weight gain or food consumption^[4].
Phenelzine (15 mg/kg; IP, 15 minutes post-injury) sulfate reduces acrolein and 4-HNE levels and improves recovery in a rat spinal cord injury (SCI) model^[1].
Phenelzine (aquarium water) sulfate mitigates paraquat-induced neurotoxicity in zebrafish by reducing oxidative stress and preserving dopamine levels and promotes axonal regrowth and remyelination in a zebrafish SCI model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female C57BL/6 micEAE was induced in female C57/BL mice with MOG35-55 (HY-P1240)(subcutaneous injection).^[5]
Dosage:	15 mg/kg
Administration:	IP; daily, for 28 days
Result:	Reduced disease severity in the chronic phase and was associated with substantial improvements in exploratory behavior. Showed a normalization of 5-HT levels in the ventral horn of the spinal cord that might account for the improvements in behavioral outcomes.

Animal Model:	Rats; traumatic brain injury (TBI) model, induced by controlled cortical impact (CCI-TBI)^[1]
Dosage:	15 mg/kg
Administration:	IP; once; 15 minutes post-injury
Result:	Prevented the decrease in respiratory control ratio, increased cortical tissue sparing from 86 to 97%, and reduced 4-HNE levels in mitochondria.

Animal Model:	Gerbils (male, 8 weeks); global ischemia model, induced by carotid ligation for 5 minutes followed by reperfusion^[1]
Dosage:	15 mg/kg, 30 mg/kg
Administration:	IP; once daily; 6 days
Result:	Significantly attenuated neuronal loss in the hippocampal CA1 region compared to ischemia-vehicle gerbils.

Animal Model:	C57BL/6 mice (male, 9 weeks); no disease model^[4]
Dosage:	31.6 mg/kg
Administration:	Drinking water; once daily; 12 weeks
Result:	Exhibited lower body fat content, subcutaneous WAT mass and lipid content in skeletal muscles than control, without decreased body weight gain or food consumption. Phenelzine impaired the lipogenic but not the antilipolytic actions of insulin in WAT. Lowered MAO activity and hydrogen peroxide release in WAT. Decreased phosphoenolpyruvate carboxykinase (PEPCK) expression in subcutaneous WAT.

Animal Model:	C57BL/6 mice (male, 9 weeks); no disease model^[4]
Dosage:	31.6 mg/kg
Administration:	Drinking water; once daily; 12 weeks
Result:	Lowered non-fasting blood glucose levels.

Clinical Trial

Molecular Weight

234.27

Formula

C₈H₁₄N₂O₄S

CAS No.

156-51-4

Appearance

Solid

Color

White to off-white

SMILES

NNCCC1=CC=CC=C1.O=S(O)(O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (426.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.2686 mL	21.3429 mL	42.6858 mL
5 mM	0.8537 mL	4.2686 mL	8.5372 mL
10 mM	0.4269 mL	2.1343 mL	4.2686 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (306 KB) SDS (480 KB)

COA (250 KB) HNMR (252 KB) RP-HPLC (242 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Matveychuk D, et al. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2022;42(1):225-242. [Content Brief]

[2]. Bustin KA, et al. Phenelzine-based probes reveal Secernin-3 is involved in thermal nociception. Mol Cell Neurosci. 2023;125:103842. [Content Brief]

[3]. Prusevich P, et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem Biol. 2014;9(6):1284-1293. [Content Brief]

[4]. Carpéné C, et al. Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine. Br J Pharmacol. 2018;175(12):2428-2440. [Content Brief]

[5]. Musgrave T, et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun. 2011 Nov;25(8):1677-88. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.2686 mL	21.3429 mL	42.6858 mL	106.7145 mL
	5 mM	0.8537 mL	4.2686 mL	8.5372 mL	21.3429 mL
	10 mM	0.4269 mL	2.1343 mL	4.2686 mL	10.6714 mL
	15 mM	0.2846 mL	1.4229 mL	2.8457 mL	7.1143 mL
	20 mM	0.2134 mL	1.0671 mL	2.1343 mL	5.3357 mL
	25 mM	0.1707 mL	0.8537 mL	1.7074 mL	4.2686 mL
	30 mM	0.1423 mL	0.7114 mL	1.4229 mL	3.5571 mL
	40 mM	0.1067 mL	0.5336 mL	1.0671 mL	2.6679 mL
	50 mM	0.0854 mL	0.4269 mL	0.8537 mL	2.1343 mL
	60 mM	0.0711 mL	0.3557 mL	0.7114 mL	1.7786 mL
	80 mM	0.0534 mL	0.2668 mL	0.5336 mL	1.3339 mL
	100 mM	0.0427 mL	0.2134 mL	0.4269 mL	1.0671 mL